Theraclion in full expansion in the first half of 2025

Theraclion, a company specializing in non-invasive high-intensity focused ultrasound therapy, announced a notable performance during the first half of 2025. Revenue jumped 89% to €835,000, compared to €442,000 in 2024. This increase is mainly attributed to the 30% increase in consumables sales and a 232% increase in services.

Significant progress was also made with the opening of new treatment centers in Bulgaria and Spain. Meanwhile, the completion of pivotal FDA clinical trials prepares Theraclion for a strategic launch in the United States. The arrival of a new Chief Commercial Officer marks an acceleration of expansion, particularly in the Middle East and Europe.

In short, Theraclion is strengthening its global presence with an ambitious commercial strategy and solid financial indicators.